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Abstract: Tracing the movement of new medical information from the labora-
tory to individual consumers is a challenge to communications theorists and
social scientists alike. This article adopts the position of the social study of med-
icine, which takes into account the impact of people’s perceptions of disease on
treatment decisions and outcomes, to locate instances of the movement of infor-
mation—and its limitations—in a unique setting: a metabolic disorders clinic for
HIV-positive patients. Analysis of data from a participatory observation study at
the clinic reveals that the clinician, inculcated into endocrinology, must adapt
new information to enable communication with patients, who hold a different
view of the body heavily informed by virology. This adaptation also occurs in
the reverse, as patients adjust their thinking to make room for new information
that will directly impact their treatment decisions.
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Résumé : Retracer le transfert de nouvelles informations médicales du labora-
toire au consommateur pose un défi au théoricien en communication tout autant
qu’au savant en sciences humaines. Cet article a recours aux études sociales en
médecine, où l’on étudie les perceptions des gens à l’égard de la maladie et les
effets de celle-ci sur les traitements, afin de situer des exemples de transferts
d’information dans un emplacement singulier : une clinique pour les perturba-
tions métaboliques qui traite les patients atteints du VIH. L’analyse de données
provenant d’une observation participante menée à la clinique révèle que le clin-
icien, avec son expertise en endocrinologie, doit reformuler de nouvelles infor-
mations afin de mieux communiquer avec ses patients, car ces derniers ont sur
le corps un point de vue différent, fortement influencé par la virologie. Cette
reformulation a aussi lieu dans le sens inverse, car les patients doivent ajuster
leurs perceptions afin de mieux intégrer de nouvelles informations qui auront
une portée directe sur leurs décisions à l’égard de leur traitement.
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Some biomedical events result in tremendous media coverage that alerts “the
public” or specific affected subgroups to relevant issues such as symptoms,
modes of contact, and direction and speed of spread. Big Story news coverage
often announces and tracks epidemics—SARS, West Nile virus, annual flus,
AIDS—and reports on breakthroughs in treatment, mechanisms for disease iden-
tification, vaccines for viruses, and even examples of the transformation of ordi-
nary into extraordinary medicine (using aspirin in the control of heart attack risk,
for instance). Sociologists of the media and critics in the area of culture studies
have expended considerable energy using framing theory and moral panic theory
to analyze such mass coverage of biomedical events. Both approaches underscore
the relationship between apparently neutral science writing and political opinions
and position-taking. Whatever criticism I have of these theoretical tacks (see
Patton, 2005), it is the case that sensational media moments seem to affect both
public and subcultural understandings of the body and its woes. But against what
background, frame of reference, and experiential context? Individuals do not
exist in a vacuum between highly publicized biomedical events.
Indeed, science more often proceeds incrementally and non-sensationally.
Unlike the big events, which are communicated directly to consumers via the
media, the bulk of new information is conveyed person to person, from clinicians
and medical paraprofessionals to their patients. The media-consumer relationship
is complex and dynamic, affected as much by news outlets’ financial interests and
science writers’ professional ethics as it is by the multidimensional possibilities
for interpretation. But the ordinary case of moving quotidian updates to knowl-
edge from the research lab to the clinic is even more complex, or at least less the-
orized; in the drifting and shifting of bio-knowledge there are countless
opportunities for professionals and patients to call forth and remake the “facts”
that are to be applied in the practical logics of bodily care.
The basic process looks straightforward enough: physicians from many sub-
disciplines learn about new medicines, diseases, diagnostic strategies, and prog-
noses from a range of sources, including meetings with drug representatives,
academic or professional conferences, medical journals, subspecialty newsletters,
and, of course, from their close circle of trusted colleagues. Doctors pass their
new knowledge along to other clinicians and to paraprofessionals who, in turn,
educate patients. Increasingly, as practitioners and community members collabo-
rate in knowledge translation, paraprofessionals also educate peer educators who
themselves go on to educate their constituencies. Of course, laypeople also snatch
information straight from medical journals and conferences—knowledge
activists and opinion leaders within health and disease constituencies filter sci-
ence for others, sometimes informally, but also through quasi-official community
media such as newsletters, Internet-based interest groups, and individual blog-
gers, those fractious, self-publicizing, and non-delegated opinionists who recall
the pamphleteers of the early French and American Republics.
This general description, however, nowhere near fulfills the ambitions of an
older sociology of science, which hoped to be able to predict the flow of infor-
mation through society—a project that seems near impossible now, with so many
way stations between lab and layperson. Rather than chart this complex system
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of senders and receivers operating across the multiple layers of scientists’, doc-
tors’, and patients’ investments and strategies, it might be more productive to
delaminate the composite object we call “medical information.” Starting in the
clinic itself, we can build up a picture of the points of incongruity—resulting var-
iously from professional norms and identities, differential access to background
information necessary to “make sense” of new information, subcultural sensibil-
ities, patients’ subterfuge—that operate as constraints on the potentially limitless
polysemy and unchecked mobility of “facts.”
The examples I work through in this article point to specific places and play-
ers as they confront a new or re-contextualized medical “fact” and then work it
into a conceptual framework that initially seems unable to incorporate it. In this
analysis of my ethnographic fieldwork in a specialized clinic, I describe the reac-
tions of HIV-positive people—mostly gay men—and their doctor as they work
through new medical facts about metabolic issues like cholesterol levels. The
majority of these patients arrive at this clinic already steeped in a knowledge set
they have acquired in their early confrontation with virology, the specialty that
has long dominated treatment for HIV. First, I find the trace evidence of their
prior assimilation to the characteristic mode of thinking about the body belong-
ing to virology. I then demonstrate the staying power of patients’ worked and
incorporated version of virology by examining moments when they deploy this
framework to “understand lipids” by reworking and incorporating facts from a
science (endocrinology) with a rather different body-logic as they try to align
their HIV diagnosis with their new diagnosis of a metabolic disorder.
Although I report doctor-patient conversations in my findings, I do not
understand these to be events during which medical facts actually flow between
individuals, but rather as moments in a larger, multi-way struggle between scien-
tific subdisciplines and among practitioners and patients, a struggle in which cli-
nicians with different levels and forms of power are forced to adapt to each other
indirectly through their negotiation of a more or less shared language and per-
spective with their patients. What we see is not only the quotidian conveyance of
minor changes in medico-scientific knowledge, but also the unstated hybridiza-
tion of medicine in clinical practice. The implication of this study is that there is
likely no single moment in which patients arrive at a “correct” understanding of
their diagnosis, nor is there a single moment in which clinicians deem the
patient’s understanding to be sufficient to the clinical goals (largely, adherence to
medications and physical regimens), but rather, the clinician, patient, and multi-
ple disciplines that they embody are already shifting sands upon which to build
“communication”: individual clinicians and patients make do within the larger
domain of changing science and changing clinical practice.
Research context and method
From summer 2003 through winter 2004 I conducted a pilot study (The
Understanding Lipids Project) in a major North American city at a specialized
clinic for HIV-positive people experiencing a range of cholesterol, blood sugar,
and morphological changes.1 There, a doctor and several nutritionists educate and
deliver services to HIV-positive persons experiencing metabolic problems related
to HIV, HIV treatment, and “lifestyle factors” (diet, exercise, smoking) that do
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not differ from those of non-HIV patients. During the time of my study, this set
of metabolic problems was undergoing a renaming—from “HIV lipodystrophy”
to “HIV Metabolic Disorder.” Lipodystrophy is a general diagnosis that refers to
any atypical fat distribution—accumulation, depletion, or both—and is a lively
area of research and clinical practice outside the world of HIV. In people with
HIV, accumulation takes place in the abdomen, breasts, and back of the neck, and
depletion is most prominent in the face, forearms, and lower legs. We know much
more today about the mechanisms of this lipodystrophy, and I was conducting my
clinical ethnography during the period when research results were flowing in and
important theoretical shifts were moving the field of HIV endocrinology into a
more prominent position in the larger field of AIDS medicine. Today, we under-
stand that fat accumulation on the belly and neck are likely related to specific
medications, while the peripheral body depletion seems related to the long-term
effects of HIV itself. But at the time of my pilot study, these “facts” were still
being produced by clinical observation, patients’ histories, controlled studies, and
via advocacy media and folk terms used by people living with HIV. (“Crix belly,”
named for the drug Crixivan, for example, proved an accurate folk diagnosis of
the cause of dramatic bellies.)
The visible effects of HIV Metabolic Disorder prompted patients to request
referral to the clinic, but there are clinical signs for the “dislipidemias” that
prompt physician referrals. These signs that fat storage molecules are out of nor-
mal range or ratio are usually discovered in the course of standard, simple cho-
lesterol tests. But the normal cholesterol tests are based on bodies not otherwise
damaged by a retrovirus or the medications that combat it; as the science of HIV
metabolics emerged, more refined measures of fat molecule size and ratio were
needed to distinguish between side effect–induced changes of little clinical con-
sequence and true underlying conditions that had been tipped into the cardiovas-
cular danger zone exacerbated by the body’s experience with HIV and HIV
medication.
The patients I saw experienced some combination of these effects as well as
bone density loss, muscle mass loss, generalized fatigue (less clearly related to
HIV treatment but likely a result of linked changes in the mitochondria), and
incremental changes in blood sugar levels. Because knowledge about the effects
of HIV and HIV treatments on the body emerged rapidly during the period of my
pilot study, the professional standing of “the lipids guys” improved and was soon
deemed a subspecialty—HIV endocrinology—that belonged neither completely
to HIV medicine nor to endocrinology.2 As we will see later, patients and the HIV
endocrinology specialist had to negotiate not only the rapidly changing science of
HIV metabolics, but also the rising professional status of HIV endocrinology.
The research project included clinical ethnography, observation of educa-
tional forums offered by the local HIV treatment information/advocacy group,
interviews with treatment information advocates, and interviews with poor peo-
ple—predominantly women—who did not attend this clinic but were potentially
experiencing HIV treatment–related side effects.3 Patients were referred to the
clinic through several routes. The majority—gay men who had been living with
HIV for five years or more—were patients of the hospital-based HIV clinic and
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were referred by a clinician patients frequently referred to as their “AIDS doctor.”
A sizeable portion of the gay men, however, came from competing medical prac-
tices that were founded as the politics and ideologies of HIV treatment evolved
and as the medical funding agencies experimented with different forms of reim-
bursement to group medical practices that managed specific patient populations.
In these cases, the referring physician could have been a general practitioner or
an HIV specialist associated with an explicitly or implicitly gay- or HIV-focused
practice. The last small group, which included the few women and the not
insignificant number of heterosexual men from outside the city core, came
directly from a general practitioner.4
The clinic was conducted for a half day most weeks, and I attended about half
of the sessions offered over the course of a year. During most sessions, I focused
entirely on one clinician (doctor or nutritionist). Some days I followed new
patients through the set of appointments that comprised their intake process.
Intake patients were supposed to see a nutritionist and most did, but few patients
were referred back to nutritionists after this initial session. On rare occasions,
patients would ask to see the nutritionist again, but it was not clear to me that the
doctor had access to information from those sessions. During my study, clinical
nutritionists, in conjunction with the main HIV research unit, conducted their
own study focused on health outcomes. On several days, I followed patients
through their interview for this second study. Several clinical trials of drugs for
managing HIV Metabolic Disorder were underway, and, during some of the clin-
ical sessions I observed, patients were recruited to these studies. It is probably
important to note here that because of the politics of drug approval early in the
epidemic (and still, in relation to new classes of anti-HIV drugs or “salvage” ther-
apies), most people with HIV could only get medications by enrolling in a clini-
cal trial. Thus, since the vast majority of the people I observed were long-term
survivors of HIV, they were also veterans of drug trials and research projects. In
a process parallel to protocols for gaining consent from patients for other clini-
cians to observe clinical sessions, the physician or other clinician explained who
I was and asked patients for consent for me to observe.
The appointments with the physician occurred in rapid succession and could
be as short as five minutes. The consultation room was fairly large. However,
multiple specialists used the room, and they had informally divided up the space.
The result was that in our sessions we huddled fairly tightly around a desk. The
physical exam space was in an alcove on the far side of the L-shaped space from
where I was perched, and the doctor pulled a curtain across the area when he con-
ducted the physical exam. I could hear the exam and see the doctor, but I could
not see the patients. Except during the initial session, the doctor took very few
notes with the patient present and instead dictated all of his notes after the ses-
sion. I followed this lead, taking no notes with the patient present because I
believed it would be intrusive. Even when the doctor did take notes, I thought it
would trouble the patients to see two people making different observations and,
hence, writing at quite different moments during the session. I therefore made
quick notes between patients while the doctor escorted the outgoing patient down
the hall and came back with the next. At the end of each day, I elaborated on my
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notes, and these are what I use as my record of the sessions. I did not request, nor
did I want, access to the patients’ files; if I needed clarifying information about a
patient—which was rare, and usually confined to their age or linguistic cate-
gory—I asked the doctor. My field notes also record information he chose to offer
me as well as his way of teaching medical students, medical fellows, and allied
health professionals who came to observe his clinic. On two occasions, the doc-
tor was visited by drug representatives, and these encounters are also recorded, as
are the doctor’s public lectures that I attended during the time while I was study-
ing his clinic.
Despite the limitations on my note taking, I improved my data collection
after the first few sessions by creating a data collection form (see Figure 1) that
ensured I used a consistent measure of patient engagement and knowledge, and
consistently recorded the nature of their condition. My transcriptions of conver-
sations were entered in the lower, open half of the form. 
Figure 1: Data collection form
Date ____________ Contact ___________ Present ______________
Length of Time ________ Intake/ Follow Up ___________________
Age ____ Race/Ethnicity ________________________ M/F _______
High Cholesterol ____ Primary Wasting ____ Redistribution ______
Diabetes ____ P/S ____ Cervical Humps ____ Smoker ___________
exercise ___________________ wt gain ____ wt loss ____________
PT: (Patient) _____________________________________________
CO: (Chief Complaint) _____________________________________
DX (Diagnosis): __________________________________________
RX: (Treatment): _________________________________________
Pt Knowledge/engagement: _________________________________
List of meds, use of “lipids” terminology ______________________
Asks questions (elaborate) __________________________________
Social dimensions, diet, exercise _____________________________
Of the 100+ appointments I observed, about 20% were follow-up appointments
with individuals I had seen earlier, thus over the course of my study, I saw about
20% of the patients who attended the clinic that year. I observed about 20
patients twice and about 5 more than twice. I found the sessions highly rou-
tinized, but at the same time, personalized, since the doctor had an amazing
capacity to remember details like patients’ hobbies and activities. Intakes took
between 15 and 25 minutes, while follow-up appointments were generally
between 5 and 7 minutes, with occasional appointments of 15 minutes. In gen-
eral, I found the physician exceptionally good at explaining test scores, the role
of drugs, and the current understanding of HIV Metabolic Disorder. Because he
was so consistent in conveying information, I was able to pay close attention to
the small moments when patients could not enter into the epistemological uni-
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verse of the “lipids guy” (so named by one of the patients I observed) and instead
attempted to fit the doctor’s “facts” into their existing patient logic.
Theoretical framework
In my work on HIV globally and locally, I adopt the general theoretical position
that is now often called the social study of medicine (SSM), a close cousin of the
earlier social study of science (SSS), which examined how scientists become sci-
entists and how their professional cultures produce and use knowledge (Becker,
1961, 1993; Crane, 1972; Harding, 1991; Knorr-Cetina, 1981; Latour & Woolgar,
1979; Rosenberg, 1976). A hallmark of SSS that makes it particularly extendable
to the social study of medicine is the combined use of ethnographic fieldwork in
scientific laboratories, archival research in the history of science, and critical
analysis of literature and arts that describe science or scientific worldviews. As
distinguished from almost all other positions in the study of science, the key find-
ing of the multidisciplinary field of SSS is that “good research results” in science
are less the rational outcome of following a strict scientific method than a contin-
gent—sometimes even transient—creation of “knowledge” that arises from sci-
entists’ ability to innovate conceptually, to manage the unexpected in the actual
research setting, and to persuasively argue, within the specific rhetoric of science,
for the validity of a scientist’s work.
Applied to biomedicine, this style of research examines how health-related
sciences and clinical professions collaborate on disease problems even when their
conceptions of diagnosis, origin, and social effects of a disease differ (cf. Epstein,
1996; Fleck, 1935/1979; Gilman, 1985; Latour, 1988; Mol, 2002; Patton, 1990,
1996; Swanson, Patton, McNamara, & Forsythe, 1992). Like SSS, the social
study of medicine is intrinsically multi-method and transdisciplinary, requiring
researchers to produce and examine a wide range of evidence gathered through
multiple research strategies—such as discourse analysis of media and profes-
sional literature, historical research, and ethnographic study of clinical practice—
in order to understand the information sources and interpretation styles used by
policymakers and citizens when they evaluate proposals for managing public
health problems (cf. Brandt, 1985; Patton, 2002; Shah, 2001; Starr, 1982). In
addition, SSM explores specific ways clinicians, affected groups or individuals,
and the public as a whole come to perceive a disease, how public perceptions in
turn shape clinicians’ perceptions of affected patients, and how such perceptual
complexes inform patients’ ways of seeking help (Goldstein, 2000; King, 2006;
Martin, 1994; O’Connor, 1995). This approach takes into account both the clini-
cian/scientist’s and the client’s perspective on the “medicine” and medical prac-
tice that unite them.
Applied in the case I explore here, the approach asks us to consider both the
re-emergence of endocrinology in the context of HIV and the way its particular
conceptual framework is taken up by people with HIV and the various people
who serve them. From the perspective of SSM, the HIV metabolic disorders
clinic is not simply the place where patients learn new information, but the scene
of a subtle disciplinary shift within the medico-science concerned with AIDS. In
this situation, and many other cases of mobile knowledge, clinicians’ and advo-
cates’ professional values, personal motivations for working in the field of HIV,
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and beliefs about their clients’/community’s capacity to comprehend scientific
information underpin their strategy for working over the facts that are in play in
each momentary encounter. Similarly, HIV-positive persons come from varying
social and cultural milieus, which affects how they make treatment decisions uti-
lizing multiple different (and often contradictory) understandings of health.
As a clinical ethnographer, I located my “field site” between two cultures:
that of virology, exhibited in trace form in the mode of understanding presented
by the patients, and that of endocrinology, represented in the information and pre-
sentational style of the doctor whom I studied. In my analysis of this space, I do
not assume that medical knowledge is incremental, but rather suppose that differ-
ent subdisciplines may represent rather different logics or, as Ludwig Fleck
(1935/1979), from whom I have developed this framework (Patton, 1990, 2002),
called them, “thoughtstyles,”5 enabling a rhetorical analysis of the moves in each
subdiscipline as a marker of its underlying thoughtstyle. In the past, I have
focused on reporters’ attempts to reconcile or move between competing logics.
Here, I examine patients and doctors grappling with contrasting ways of under-
standing the body. For brevity, I schematize the differences between virology and
endocrinology in Figure 2.
Figure 2: Thoughtstyles of competing disciplines in HIV care
The doctor I studied is well regarded among patients and described by colleagues
as a good communicator. He is also a popular—almost charismatic—speaker at
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Virology
Linear narrative from 
infection to cure
“Evil” from outside
“Bullets” against the virus
Additive logic—if one bullet
fails, replace with another
Hit multiple targets
Use strongest tolerated drug
Objective: maintain patient 
at “undetectable virus”
Endocrinology
Progress and regress in different 
organ systems
Malfunctions from multiple sources—
family, lifestyle, medications, disease
Balance among elements
Add less and more to find middle
ground
Try multiple equivalent solutions 
(diet, exercise, food supplements, 
medications)
Modify lifestyle before prescribing
medications
Objective: help patient stay within a
range of balanced clinical measures
and maintain a mainstream “healthy
lifestyle” (exercise, no smoking, bal-
anced diet, reduced stress)
educational sessions organized by the clinic and by local AIDS organizations.
This clinician is from a working-class background and went to a major Canadian
medical school. It was difficult to sort out whether it was this class difference, the
lesser standing of his specialty, or both6 that made him appear deferential toward
the scientific knowledge of the HIV doctors and researchers with whom he inter-
acted in the clinic and in public presentations. He has practised in a number of
major North American cities and has been in his present postion for more than a
decade. An outdoorsy sort of person, he is very fit and close in age to the major-
ity of his patients. With his own evidence of middle-age spread, he is highly sym-
pathetic toward his patients’ struggle with diet, exercise, and aging. Interestingly,
while he often empathizes with their difficulty in maintaining a good diet, he is
adamant about exercise, often telling clients that “exercise is better than any pill
I can give you” (Field notes, 0062, 12/11/03). Thus, although he promotes some
diet changes and refers patients to the nutritionists, he does not seem to believe
this will make much difference for the majority of his patients. In one case, when
a nutrition- and fitness-conscious patient asked if he could further improve his
cholesterol values through diet, the doctor replied: “No, your numbers are caused
by your medications.” On the other hand, I observed that he also trod lightly in
relation to patients’ smoking habits. When I asked him why, without hesitation he
offered a rationale that hints at his understanding of the specific fragilities of
building trust with his patients:
MD: He needs to quit smoking. I tell them to quit but not very force-
fully—if they don’t, they feel they’ve disappointed me. (Field notes,
0031, 06/27/03)
As I suggested in the introduction, when I look for the traces of virological
thinking in the patients, I do not imagine that they had a complete or transparent
understanding of what they had been told by doctors, read in magazines or online,
or discussed with their friends. Rather, I hope to show a general consistency to
the background logic brought by patients to their encounter with the HIV endocri-
nologist. But I first want to make two more notes here about other knowledge
sources, with other potentially compounding investments and rhetorical forms,
that are inflected in my field setting.
First, despite bans on direct-to-consumer pharmaceutical advertising in
Canada, Canadians still see much of this type of advertising through American
media beamed into the country by satellite. Thus, the individuals in my study may
well have learned about their cholesterol and cholesterol medication options
through popular media sources. It is far less common, however, for Canadian than
for American medical consumers to actually get cholesterol tests: coming from
the U.S., I was initially surprised that very few of the patients referred to the
lipids clinic had ever had a cholesterol test before the one that resulted in their
referral. Thus, as compared to the U.S., I found Canada to have fewer non-clini-
cal and clinical moments in which to “understand lipids.”
Second, although AIDS organizations have diversified their client base since
the early days of the epidemic, when they served primarily gay men, it is still
uncommon to see anyone other than gay men actively participating in treatment
information activities (attending talks and workshops, reading magazines
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directed at HIV-positive persons, becoming volunteer information activists). As I
discuss in my notes, there are complex issues related to how service for women
evolved, and the implications of this history for recognition of HIV Metabolic
Disorder are reported elsewhere (see Patton, in press).
Results
Traces of virology
The vast majority of the patients were very conversant with the terms related to
HIV and with their HIV medications. More than a third carried a list of their med-
ications, and several brought diaries that recorded their past medications, includ-
ing when each drug was started and stopped. Some used the colour or function of
the pill to identify it rather than its name, but the vast majority knew the trade
names for their half-dozen or more medications. Acknowledging the expertise of
his patients as a group, and expecting that a concordant discourse had emerged
with seasoned follow-up patients, the doctor generally initiated discussion with
the term “medication” and the individual trade names, and only switched to ver-
nacular terms like “pills” or “your HIV medications” or “the one you take for
asthma” in the face of communicative uncertainty. During follow-up visits, the
doctor frequently read the list of the medications agreed upon in the previous visit
from the patient’s chart and then asked if these had changed. Rarely were patients
unsure about their HIV medications, but frequently they had not incorporated the
names of their metabolic disorder–related medications, and the doctor would use
trade names for HIV medications, but resort to terms like “the orange pill” or “the
one you take for your diabetes” for the drugs he prescribed.
My use of the data collection form and ranking of patient knowledge, devel-
oped in relation to simple displays of patient knowledge and the subtle interac-
tions over the register (vernacular versus technical terms) reflect my own
expectation, parallel to the doctor’s, of what patients might know and how easily
they might switch to, or incorporate, the new logic of endocrinology offered by
the doctor. But while he and I converged in our expectations for patient perform-
ance, I was also able to see that his stock opening for intake exams, while appar-
ently neutral, actually initiated the patients’ reorientation from virology to
endocrinology.
The doctor always began the intake with the question “What is your under-
standing of why you are here?” This explicitly invited the patient to put their
knowledge on the table and gave the doctor an opportunity to identify the appro-
priate register in which to move through the process of getting and giving (what
was likely to be new) information. More generally, the question also invited a
spatio-temporal narrative—“Why are you here?”—and many patients used this
opening to provide an account of the chain of events within previous clinical
spaces that had led to their presence at the clinic. There was subtle but consistent
evidence of virology’s temporal narrative in these replies, since many patients
tagged their cholesterol changes to the temporal framing of their viral progression
and their changing medications, themselves implicitly constituted in a temporal
sequence. To clinicians and laypeople highly familiar with the decade-long his-
tory of anti-HIV combination therapies, the names of combinations provide both
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historical markers (X combination came into use at X time) and a gauge of per-
sonal progression (X combo is used early in the HIV progression, Y later, and Z—
the most powerful and toxic—when there are no options left). One patient
succinctly exhibited his assumption that he and the HIV endocrinologist share the
same “time of AIDS” and that this knowledge of the spatio-temporal terms of
viral progression and anti-retroviral development is all “common knowledge”:
“Every time they get to the edge and have nothing left for me something new
comes out” (Field notes, 0041, 07/31/03). I want to look more closely now at sev-
eral sessions in which patients offered their logic and in which the doctor tried to
introduce his.
Coming into the country: Meeting endocrinology head on
On intake, few patients had much understanding of the role of cholesterol or the
significance of their test values. The following exchange, from a 25-minute
intake with a 40-year-old White male referred from a general practice, is a sort of
median case of first encounters with HIV endocrinology. The patient is a good
historian of his medical life and presented these facts in a straight narrative
sequence whose underlying logic was “time with HIV.” For example, he pin-
pointed his herpes zoster as the opportunistic infection that enabled his doctor to
reveal his underlying HIV infection. Thus, while he appeared to have a solid basis
for transacting new medical facts, his acquisition of medical concepts seemed
largely to have taken place within the logical framework of virology. However, in
general, I classified this patient as less fully acculturated to virology. Referred by
a general practitioner, he has less facility with his HIV information than the
patients who came via the city’s main HIV practices.
MD: What is your understanding of why you are here?
Pt: I guess it’s because of the high cholesterol.
MD: What pills are you taking?
Pt: The orange one. . . [thinks]. I usually have a list.
MD: [discussing the laboratory test values that resulted in the referral] It
was because your triglycerides are too high.
Pt: What are those? I just know that whatever it was my doctor was look-
ing at was 8.
MD: It’s down to 6 now. That’s very good.
[MD conducts family history and patient history and learns that the
patient discovered he was HIV-positive in 1989, when he had “zoster,”
which MD corrects to “herpes zoster.”]
Pt: I’m on high blood pressure medication.
MD: [Pt does not know medication name, but MD figures this out from
the chart.] That is a beta blocker. I want to change you from that to some-
thing called an ACE inhibitor. I don’t think a young guy like you needs
to be on beta blockers.
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[MD takes blood pressure]: That’s really good, 110/65.
Pt: So maybe I can go off that altogether?
MD: I’d like to keep you on something since it has a protective value.
Pt [clearly not really understanding what protective value means]: Well,
okay. (Field notes, 0048, 12/04/03)
In general, follow-up patients acclimatized to the concepts of endocrinology
related to their lipids profiles. However, few used the terms “HDL,” “LDL,” and
“triglycerides.” Rather, they called these “the good cholesterol” (HDL), “the bad
cholesterol” (LDL), and “trics” or “that other one” (triglycerides). These patients
had a good sense of what their target values were, but rarely accurately evaluated
the magnitude of change in their numbers. The following 40ish-year-old White
male follow-up patient is quite a card, but otherwise had a typical level of knowl-
edge on follow-up. In the following exchange, aside from the banter with his doc-
tor, we can see both parties negotiating what are to be the objective measures of
successful treatment. Although the patient seemed not to initially understand
magnitude changes represented through the mathematics underlying the lab val-
ues (and was fond of bargaining with his doctor!), he incorporated lab measures
by the end of the 15-minute session.
MD [looking at the lab sheet]: I want to get your trics down.
Pt: What’s the range?
MD: They can go up to 100.
Pt: Well, if I’m 5, I’d say I’m doing pretty good!
MD: I like to see them around 3.
[After some discussion about treatment plan:]
MD: Exercise is better than any pill I can give you. What exercise do you
do?
Pt [clicks his thumbs, meaning channel surfing]: What, do you want me
to switch hands? Seriously, I pay $45 per month for the gym and I don’t
go. Want to hit me? Someone should!
MD: If you walk every day you’ll see your belt go down one notch.
Pt: That’s good!
MD: I want to get you back in here in 8 months, not 6 like I said before.
I’m going to give you the extra two months to bring your weight down.
And your belt. This gives us something objective to shoot for. See you in
July, one notch tighter on your belt.
Pt: And 3 [meaning on his triglycerides]! (Field notes, 0062, 12/11/03)
Based on their experience in the viral-logic world of HIV care, the patients
have become accustomed to the idea that the antiviral medication goal is to ren-
der their HIV “undetectable,” which many refer to as “zero load.” (Indeed, the
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HIV endocrinologist acceded to one patient’s use of this term, only to be cor-
rected by the man’s wife, who said, “Not zero, ‘undetectable.’”) Of the many
reframings of their bodies that their acculturation to endocrinology would entail,
patients had a particularly difficult time accepting the idea that good and bad cho-
lesterol vary inversely; that their treatment plan was not aimed at “zero” but at
some other number; and that in many cases the relative relationship between
“good,” “bad,” and “the other one” is an important measure of treatment progress.
Indeed, the doctor was greeted with extreme skepticism when, after he had
asserted particular values as the goal but the patient’s medication had not
achieved these, the doctor was nevertheless satisfied that lowering the bad cho-
lesterol was more important than raising the good cholesterol.
Soft logic and uncertain solutions
Coming into the country of endocrinology required more than simply learning new
math. It also required patients to change their expectations about the doctor’s role
in interpreting lab results and choosing medications. Early HIV drug regimens
were very standardized—drugs were titrated to patients based on their body
weight and CD-4 counts. As early treatments stopped working and new combina-
tion therapies emerged, there was also a sequence in which the various drugs were
given. With the twin advances in HIV therapy and HIV substrain diagnosis—that
is, with the rise of drugs that target different aspects of viral reproduction and phe-
notyping of viral strains—it has become possible to offer “boutique” treatment
combinations. Clinicians now know which drug combination is most likely to be
effective with which viral strains. Especially when an individual patient’s own
virus has mutated, we now know what drugs are likely to work best next.
Ten or fifteen years ago, before this ability to tailor treatment to virus (notice:
the treatment is matched to the virus, not to the person who hosts it), patients
developed an expectation: everyone receives more or less the same drugs for the
same lab values. Despite advanced knowledge of viral strains, this expectation
has stuck: genotyping is just another test to determine which drug and in what
dose: lab value(s) X = treatment Y. Although the possibility of metabolic side
effects has entered into the equation, side effects—good and bad—are largely
only allowed to influence HIV treatment decisions when two drug combinations
are roughly equivalent in terms of viral suppression, but one has fewer side
effects. Indeed, patients who stated that their AIDS docs had switched their drug
combination to one that was more effective for them, but had metabolic side
effects, had the expectation that the HIV endocrinologist had a list of standard-
ized treatments to “fix” problems caused by the high-tech HIV medications.
In the following exchange, a 43-year-old White male highly familiar with HIV
medications expresses ongoing confusion about the lipids-related lab values. In his
session, he did not ask for a change in his current HIV medication (which would
likely have resolved the lipids problem), but instead looked to the HIV endocrinol-
ogist to “add” another drug to the arsenal. When the MD seemed less than deci-
sive about the efficacy of solving the HIV medication–driven change in
triglycerides with the relatively wimpy tried-and-true standard treatment (a statin),
the patient expressed perplexity at the lab values rather than at the reality that HIV
endocrinology does not work via the hit-hard logic of HIV combination therapies.
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The session got back on track when the MD offered the patient a place in a clini-
cal trial, re-establishing himself as a scientist and the patient’s body as the scene
of a potential scientific breakthrough. But at the end of the session, the patient
seemed unconvinced about the new subdiscipline he had encountered and about
the gradualist approach of its practitioner. The patient seemed to want to gain con-
trol over his treatment decisions by equalizing their knowledge: if only he under-
stood the “numbers” he would be able to plug these into a standard formula and
decide for himself what cholesterol drug to add to his combination therapy:
MD: What is your understanding of why you are here?
Pt [reports viral load and CD-4 counts. He says he started protease
inhibitors in January]: I’m a poster boy for PI! [However, he has experi-
enced a very great increase in triglycerides, which he and his doctor
believe is driven by Retonavir.]
[MD reviews lab values.]
Pt: These are new numbers for me.
[MD places him on an entry-level statin and discusses the patient’s eligi-
bility for the trial of a new medication.]
Pt [interested in the trial but says again]: I’m not used to these numbers.
(Field notes, 0025, 06/27/03)
In a context in which the dominant narrative had the AIDS virus (or, “some-
thing bad from outside”) being reduced to near nothing (“killed”) with drugs
(“something good from the outside”—even if toxic and rife with adverse effects),
the HIV medication–prescribing doctor developed as more or less a technician,
fitting drug combinations to lab values through a formula that admitted no art or
judgment. This sense of the doctor as technician has been reinforced in highly
publicized mass distribution programs (such as the World Health Organization’s
“3X5”—three million people on anti-retrovirals by 2005) that rest on an assump-
tion that HIV prescription, at least in “low resource” countries, is largely formu-
laic and no longer requires the level of doctoring perceived to exist in the
postindustrial world.
By contrast, the lipids problem is “inside”—whatever its multiple and inter-
acting causes—and can be “fixed” through a range of adjustments to dynamic
health practices, including exercise, diet supplements, and pharmaceuticals. As
opposed to virology, which has exhaustive means of identifying minute differ-
ences in viral strains and offers multiple drug combinations to kill it, endocrinol-
ogy (or at least the aspects of the discipline seen by patients at the time of my
research) appears to provide only rough guidelines to doctors. HIV endocrinology
dramatically foregrounds clinical judgment7 about what treatments to offer, while
state-of-the-art virological HIV treatment makes judgment appear to be an enact-
ment of technical standards. Activist HIV patients conduct their own research and
present their doctors with their options, asserting themselves as equally capable of
“reading the literature.” Stepping into the world of endocrinology thus disrupts
these patients’ expectation of how they will be able to participate in their own care.
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On one hand, since so much of what they will be asked to do involves self-moni-
toring of lifestyle, they could see themselves as far more in control of their care
than in situations where they must rely on tests and high-tech drugs. On the other
hand, because HIV endocrinology rests so heavily on the old-fashioned art of clin-
ical judgment, patients seem to experience themselves as lacking in the essential
elements (first, information; second understanding) they need to even the playing
field between the doctor’s knowledge and lay knowledge.
In the absence of a vocabulary sufficient to the bridge the knowledge/power
gap between patients’ work in the understanding of virology and the new
demands of endocrinology, the doctor at the lipids clinic asserts his clinical judg-
ment as a “strategy.” In the following long-ish follow-up appointment with a
roughly 45-year-old White male patient, the doctor emphasized clinical judgment
by assigning the patient to the status of a highly particular “case” rather than a
mere member of a class whose needs might be known in advance. However, the
doctor’s approach failed, and he resorted to a logic like that of virology. Given
this opening to his preferred logic, the patient dragged the doctor across the epis-
temological divide and tried to initiate a discussion of the lab values related to
virology. The doctor rejected this conversation by juxtaposing the clinical judg-
ment he had just displayed with what he implicitly evaluated as the simplistic,
technocratic knowledge of HIV doctors:
[Pt has very low “good cholesterol” and is very disappointed that this has
not improved more.]
Pt: Is there anything I can do with diet?
MD: My tactic is to drive the cholesterol as low as possible. That means
the good gets very low, but that isn’t that big of an issue.
[Pt then asks if his T-cell counts are on the lab sheet. MD shows him the
lab report and the parts related to metabolics.]
Pt: But do you have the T-cell or whatever numbers?
MD: I’ll let the T-cell counters deal with that! (Field notes, 0061,
12/11/03)
Patients brought a range of knowledge to their encounter with endocrinology
in the clinical setting, and, especially at intake, the doctor had to be quick on his
feet to guess what background knowledge was being put into play and whether a
patient could remain in the higher register of communication (including technical
terms and names) or would move to the vernacular. In the following 30-minute
intake with a 45-year-old White male who is still working as a stone mason, we
see the doctor engage in complex manoeuvres as he recovers from the mild insult
by the patient that his knowledge was somehow less clear than that of the AIDS
doctors with whom the patient is familiar. The doctor answered a range of ques-
tions not completely related to the patient’s metabolic problem, while trying to
keep the session on track in the process of developing a treatment plan for severe
dislipidemia. The first follow-up question raised by the patient fell squarely
within the doctor’s specialty. But it was not clear that the patient understood that
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cholesterol and wasting are parts of an underlying syndrome, or whether, bereft
of a clear expectation of what the “lipids guy” could and could not do, he was
simply going down his list of complaints:
MD: What is your understanding of why you are here?
Pt: I have high cholesterol and you are the lipids guy.
[MD collects patient history: Pt had gone off HIV meds four months, his
lipids are okay, but his viral load increased. He resumed a combination
therapy six months prior to this appointment, and his lipids declined, but
not much. As the appointment unfolds, the patient reveals that he has
seen an article in the newspaper about a new drug—Evandia.] (Field
notes, 0026, 06/27/03)
As the intake unfolds, we discover that although the patient knew he was
referred for his “high cholesterol,” he wanted to discuss another problem. But it
was unclear how he related these bodily symptoms to his clinical signs: “Is there
anything new in the wasting department?” As the doctor discussed current recon-
structive surgery options to address facial wasting, it became clear that this frank
and physical expression of his long-term HIV infection was of far more concern
to the patient than the lab values that had brought him to the clinic. While the doc-
tor was also concerned about wasting—especially the full-body wasting that
drops people below a life-sustaining BMI (Body Mass Index)—he was more con-
cerned with this patient’s cholesterol. The doctor tried to move the conversation
back to the issue of the new drug.
MD: I’d be willing to put you on that. . .
[MD addresses the patient’s concern about fatigue he has experienced on
statins—drugs like Lipitor. The patient has lots of questions about how
the new drug works, and he is especially concerned about liver toxicity.]
(Field notes, 0026, 06/27/03)
Initially, I took this concern about liver toxicity to indicate that this was a
highly and widely educated patient. However, as I observed more patients asking
about liver problems, and as I saw the doctor reply to these concerns compassion-
ately but with a subtle cue that this was not really a reasonable question, I realized
that the concern with one’s liver was another sign of the depth of patients’ accul-
turation to the concerns of HIV treatment. Having spent many years on highly
toxic drugs, they had learned to exercise great concern over their livers. Many HIV
patients undergo routine liver function tests as part of the HIV medication treat-
ment regimes, so they know they should always query their doctors about liver
complications with their medications. Nevertheless, I don’t believe many had any
concrete idea of what their liver actually does. In the closing moments of this
transaction, the patient pushed the doctor to distinguish between a lipid-control
medication that metabolized in the liver and “the other” drugs. Guessing that the
patient had some understanding of the liver as a cleansing organ, the doctor
resorted to this explanation of the action of the new class of drugs:
MD: It works in the gut—the liver never sees it.
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Pt: Where does it [the cholesterol] go?
MD [now trying to move the appointment along]: You just poop it out.
(Field notes, 0026, 06/27/03)
Recovering alternative frameworks: Offering patients new science for old logics
In these few examples I have tried to demonstrate the limitations that one
thoughtstyle—virology—puts on another—endocrinology—as medical facts are
relayed in one clinical setting. Much of the doctor-patient communication litera-
ture presumes that doctors have more power than their patients to impose mean-
ing on the facts they present. But I have suggested that the HIV endocrinologist’s
power to assert his expertise either through imparting critical information or
through the exhibition of his clinical judgment is importantly limited by the
patients’ own prior incorporation into another medical discipline’s understanding
of causal relations, treatment strategies, and the role of the doctor. But there are
other limits on the polysemy of medical information, some of which I have men-
tioned (media, subcultural knowledge), and one I want to raise here.
It has been important to me to emphasize the fundamental difference between
virology and endocrinology as the difference between the magic bullet orienta-
tion of the former and the holism of the latter (Patton, 2007). In a solid minority
of cases, patients highly acculturated to virology seemed to fairly quickly take up
the more holistic concepts of endocrinology. Consistent with my social studies in
medicine approach, I have not evaluated these as cases of smarter patients or bet-
ter explanations by the doctor. Instead, I see this as evidence of the complexity of
knowledge of patients who, however well trained as HIV patients, also already
hold mobile beliefs and engage in more complex practices of care than their HIV
medicine–prescribing doctors may realize. In the following interview with an
unusually articulate patient, we see quick movement among different approaches
to medicine, which he has incorporated into his own—apparently uncontradic-
tory—system of care. This patient is a public figure who had just entered a clin-
ical trial to repair the damage that lipodystrophy had caused to his face.
Pt [seemingly embarrassed about getting facial enhancement]: I’ve felt
so good and had so few problems; if I can make myself feel better and
keep going, why not? (Field notes, 0039, 07/24/03)
After a long discussion about green teas and their potential value for choles-
terol control, he said: “The ancients incorporated Western medicine; Westerners
should incorporate these traditions. Along with salmon oil and the other stuff.”
After some discussion about lab values, he offered the following assessment,
which calibrates the differences between virology and endocrinology and
between “medicine” and “well-being” by constructing the patient himself as a
clinical “case” in which the most important element seems to be his own subjec-
tive state, an assertion of his self-knowledge over that of both of his doctors:
Pt [makes transition from chat]: But about my case, Crestor is fabulous,
my viral load is undetectable, and I feel great. (Field notes, 0039, 07/24/03)
Through their encounters with various forms of biomedicine and their “com-
plements,” each with their own interrelationship between forms of clinical judg-
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ment and prescription, and in the context of their other, prior knowledge of their
bodies, patients adopt their own form of judgment, which gives shape to the med-
ical facts they receive. Sometimes they see themselves as a “case,” other times as
a “class”; sometimes their bodies are a battleground on which harsh drugs attack
an offending invader, sometimes they are delicate dancers in a quest to find bal-
ance among integrated organ systems. But however multiple, mobile, and com-
plex are patients’ understandings of their body and systems of care, they are not
unlimited, nor are they idiosyncratic results of infinitely complex lives. By ask-
ing not “Where does information come from?” but rather “What logics do facts
require and implement?” I hope to have sketched out an approach to understand-
ing how information moves within and across multiple power gradients and,
especially, how it is that science, produced at considerable remove from where it
is deployed, maintains the status of its original producers, even when the “facts”
make their final appearance in the hands of lay users.
Notes
1. This study was funded through a grant from the SSHRC Small Institutional Grants Programme,
and through the William and Ada Isabelle Steel Fund, and was reviewed and approved by the
Simon Fraser University Research Ethics Review Board as well as the ethics review board of
Providence Healthcare.
2. This drift from diagnosing symptoms that first appear patently on the patient’s body to the use of
clinical and laboratory signs that later enable the clinician to demonstrate the interrelated signs
and symptoms common to a “disorder” repeats the history of “AIDS” and almost all other twen-
tieth-century diagnoses. In my original research plan I admit that it was no stretch to imagine I
would find virology and endocrinology jostling for position. But it was sheer luck to have been
there exactly at the moment when the list of “adverse effects” of HIV medications and the inex-
orably unfolding tale of long-term wear and tear by the virus itself were deemed to be a single
“problem,” later redefined as HIV Metabolic Disorder. But that is a story complex enough to
merit treatment elsewhere. Fleshing it out would require more detail about how individual doc-
tors from different medical subspecialties came to recognize various symptoms and signs; how
they interpreted them; how the rapid output of research reports and the resituating of scientific
and clinical discussion from subspecialty journals and the adverse events conferences to stand-
alone HIV Metabolic Disorder publications and conference sessions came about; and how the
very rapid invention of a new market for existing and emerging “cholesterol” and “diabetes”
drugs all came together as the medium in which patient and specialist now meet.
3. Because of the complex history of service provision in the city, a substantial portion of women
with HIV go to a women’s clinic that has its own endocrinologist and nutritionist. The women
interviewed in my study did not routinely get their care at that women’s clinic, however, and
relied instead on the local providers in their impoverished neighbourhood. Among those providers
are research clinicians whose primary work is in the HIV unit in the hospital that houses the clinic
I studied and report on here. I deal with the complex biological, historical, and social factors that
have resulted in considerable sex differences in the side effects of HIV in another essay,
“Unexpected Side-Effects: Uncovering Local Impacts of Knowledge Proliferation about HIV
Metabolic Disorder in Two Distinct Populations,” in Knowledge Production and Translation in a
Globalized Era: Issues and Implications for Women’s Health (Patton, in press). 
4. I did not have access to referral information beyond what was described by patients in their
appointments. However, it was my impression that the level of understanding about HIV among
general practitioners in the region was high enough that when faced with abnormal blood sugars
or cholesterol counts, they understood that this was not necessarily independent of their patients’
HIV and required at least a preliminary assessment by an HIV endocrinology specialist.
5. Fleck argues that scientists undergo a long process of becoming acculturated to the “style of
thought” of their specialty. However, when they actually practise their science, they draw upon
logics from outside that speciality. This suggests that while “expert knowledge” has a specific
form and culture, it is more hybrid when put into play. I have interpreted Fleck—aligning his his-
tory of syphilis and its treatment with Foucault’s Birth of the Clinic (1963/1973) and Archeology
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of Knowledge (1972/1982) as well as with Pierre Bourdieu’s work on expertise, especially in
Academic Discourse (1965/1994), State Nobility (1989/1996), and Science of Science and
Reflexivity (2004)—to suggest that it is possible to roughly outline the “thoughtstyle” of a med-
ical discipline through analysis of textbooks, conferences, and clinicians’ practice.
6. In both Academic Discourse (1965/1994) and State Nobility (1989/1996), Pierre Bourdieu con-
vincingly demonstrates that the “aptitude” for various academic disciplines is linked to sociocul-
tural class. He shows that professionals in disciplines such as literature and philosophy “prefer”
creativity and expansive thinking, qualities cultivated in and valued by the upper classes, while
areas such as geography and economics rely on systematic and organized thinking precisely at the
cost of flights of fancy, qualities more nearly associated with the lower middle classes. I see no
reason to imagine why the subdisciplines within medicine—however much Canada tries to level
class within the medical training system—would not also follow along in parallel with class dif-
ferences cultivated in society at large. Certainly, there is a well-documented sex difference among
those who practise clinical subspecialties: women predominate in the fields that require traits cul-
tivated in women (family practice, paediatrics), while men predominate in fields that require mas-
culine qualities (surgery, emergency).
7. Here I am echoing the work of Alvan R. Feinstein (1967), who, more than 25 years ago, gained
renown for his highly regarded work on clinical judgment. Using a systematic approach to ana-
lyzing the “parameters” involved in clinicians’ decision-making processes, Feinstein articulated a
researchable model of clinical judgment that could be linked with clinical outcomes. In a 1994
article (Feinstein, 1994) written to counter the emerging movement that would soon be called
“evidence-based decision making,” he contested what emerged as the quantitative methods used
to, in his view and mine, eliminate clinical judgment from clinical practice by using the idealized
model of the clinical trial as the model for clinical practice. There is a much longer history to this
dance between clinical judgment and attempts to define and regulate the administration of phar-
maceuticals. Kane Race (2005) argues convincingly that from the early twentieth century on, the
very idea of scientific trials of pharmaceuticals has rested on the assumption that doctors have
poor judgment about what drugs to give a patient. And of course Michel Foucault (1963/1973)
and Georges Canguilhem (1978/1991) have detailed the longer history that underwrites both of
these authors’ assessments of the role of doctors in the history of care.
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